Belite Bio

Historical price data

Belite Bio is a clinical-stage biotech focused on developing novel oral therapies for diseases of blindness and metabolism, built on its proprietary RBP4 (Retinol Binding Protein 4) intellectual property. Its lead candidate, Tinlarebant, is in multiple late-stage trials for Geographic Atrophy (GA) and Stargardt Disease type 1 (STGD1), having secured significant regulatory designations including Breakthrough Therapy and Orphan Drug status. The company's strategy leverages a single mechanistic platform across high-unmet-need ophthalmic indications before expanding into broader metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Proprietary platform targeting Retinol Binding Protein 4 (RBP4) to modulate vitamin A transport, aiming to reduce the accumulation of toxic retinoid byproducts that drive cell death in retinal and metabolic diseases.

In GA, Belite competes against approved intravitreal C3 inhibitors (Syfovre, Izervay), differentiating on oral administration. In STGD1, it faces earlier-stage gene therapy and small molecule competitors, holding a late-stage advantage. Its RBP4 platform is mechanistically distinct from complement-focused and other visual cycle modulation approaches.